Selective targeting of 2′-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 9, 2010, Pages 2908-2911

  Vine, Kara L ^a   Locke, Julie M ^a   Bremner, John B ^a   Pyne, Stephen G ^a   Ranson, Marie ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

2 Deoxy 5 fluorouridine; Anticancer prodrug; PAI 2; Selected delivery; Targeted therapy

Indexed keywords

2' DEOXY 5 FLUORO 3' O (3 CARBOXYPROPANOYL)URIDINE; ESTER; FLOXURIDINE; PLASMINOGEN ACTIVATOR INHIBITOR; SUCCINIC ACID; UNCLASSIFIED DRUG; URIDINE; UROKINASE;

ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS;

CELL LINE, TUMOR; HUMANS; NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 2; URIDINE; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77950865527     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.03.029     Document Type: Article

References (26)

1. Meyerhardt J.A., and Mayer R.J. N. Eng. J. Med. 352 (2005) 476
2. Kelder W., Hospers G.A., and Plukker J.T. Expert Rev. Anticancer Ther. 6 (2006) 785
3. van Laar J.A., Rustum Y.M., Ackland S.P., van Groeningen C.J., and Peters G.J. Eur. J. Cancer 34 (1998) 296
4. Barbanti-Brodano G., and Fiume L. Experientia 30 (1974) 1180
5. Poznansky M.J., and Juliano R.L. Pharmacol. Rev. 36 (1984) 277
6. Goerlach A., Krauer K.G., McKenzie I.F., and Pietersz G.A. Bioconjugate Chem. 2 (1991) 96
7. Henn T.F., Garnett M.C., Chhabra S.R., Bycroft B.W., and Baldwin R.W. J. Med. Chem. 36 (1993) 1570
8. Krauer K.G., McKenzie I.F., and Pietersz G.A. Cancer Res. 52 (1992) 132
9. Pietersz G.A., and Krauer K. J. Drug Target 2 (1994) 183
10. Zhang Z., Hatta H., Ito T., and Nishimoto S. Org. Biomol. Chem. 3 (2005) 592
11. Jain R.K. J. Natl. Cancer Inst. 81 (1989) 570
12. Wu A.M., and Senter P.D. Nat. Biotechnol. 23 (2005) 1137
13. Dillman R.O. Antibody Immunocon. Radiopharm. 3 (1990) 1
14. Ranson M., Tian Z., Andronicos N.M., Rizvi S., and Allen B.J. Breast Cancer Res. Treat. 71 (2002) 149
15. Allen B.J., Tian Z., Rizvi S.M., Li Y., and Ranson M. Br. J. Cancer 88 (2003) 944
16. Li Y., Rizvi S.M., Ranson M., and Allen B.J. Br. J. Cancer 86 (2002) 1197
17. Stutchbury T.K., Al-Ejeh F., Stillfried G.E., Croucher D.R., Andrews J., Irving D., Links M., and Ranson M. Mol. Cancer Ther. 6 (2007) 203
18. Croucher D.R., Saunders D.N., Lobov S., and Ranson M. Nat. Rev. Cancer 8 (2008) 535
19. -).
20. +).
21. -).
22. Ranson M., Tian Z., Andronicos N.M., Rizvi S., and Allen B.J. Breast Cancer Res. Treat. 71 (2002) 149
23. Lobov S., Wilczynska M., Bergstrom F., Johansson L.B., and Ny T. J. Mol. Biol. 344 (2004) 1359
24. 50 value was not obtained due to limited amounts of material.
25. Andronicos N.M., and Ranson M. Br. J. Cancer 85 (2001) 909
26. Al-Ejeh F., Croucher D., and Ranson M. Exp. Cell Res. 297 (2004) 259